Mounjaro injection site rotation: what the science actually says

What did @georgia.xugc actually say?

Honestly, the transcript here is a problem. The audio captured by the fact-check tool appears to be song lyrics, not the creator's actual voice. So we're working from the caption, which is what most of her 36,600 viewers actually read.

In the caption, she makes two specific claims worth examining: first, that rotating injection sites is good practice because staying on one side "can cause scar tissue." Second, that scar tissue makes the medication "not be as effective." She's on week three of Mounjaro at what appears to be the 2.5mg starting dose, about to move to 5mg. These are the claims on the table.

Does the science back this up?

On the scar tissue question, yes, the underlying concern is real and clinically documented. Repeated subcutaneous injections at the same anatomical site can cause lipohypertrophy, which is a buildup of fatty, fibrous tissue beneath the skin. This is well-established in diabetes care literature, particularly from decades of insulin injection research.

A 2014 study by Blanco et al. in Diabetes Care found that lipohypertrophy occurred in 49.1% of insulin-injecting patients who did not rotate sites, and those patients showed higher HbA1c variability, suggesting genuinely impaired drug absorption. Tirzepatide (Mounjaro) is also a subcutaneous injection, so the biological mechanism for the same risk applies, even if there is no tirzepatide-specific lipohypertrophy trial data yet. The prescribing information for Mounjaro explicitly instructs patients to rotate injection sites with each dose. So she is correct that rotation matters.

What did they get wrong (or right)?

She got the rotation advice right, and it deserves credit because a lot of GLP-1 content on TikTok ignores injection technique entirely. The approved sites for Mounjaro are the abdomen, thigh, and upper arm. Simply switching between left and right on the same body region is better than nothing, but it is not the full picture of what rotation means clinically.

Eli Lilly's prescribing guidance specifies rotating among the three approved sites, not just mirroring sides. If she is only alternating left-to-right on, say, the abdomen, she is still repeatedly injecting the same general tissue type and depth, which reduces but does not eliminate lipohypertrophy risk over a longer injection timeline. The claim that scar tissue makes it "not as effective" is directionally accurate. Absorption from lipohypertrophic tissue is both reduced and unpredictable, which is actually the more clinically relevant risk. It is not just less drug, it is inconsistent drug delivery.

What should you actually know?

Injection technique is genuinely underrated in GLP-1 conversations online. Rotating across all three approved sites, abdomen, thigh, and upper arm, is the standard clinical recommendation, not just left versus right. Each new injection should be at least one inch from the previous site in the same region.

A few other technique points that matter: injecting into an area that is bruised, tender, or has existing lumps should be avoided. The pen should be held against the skin for the full recommended time after injection to ensure complete dose delivery. Tirzepatide should not be injected into muscle, and pinching the skin can help ensure subcutaneous placement in leaner individuals.

One more thing worth flagging: the hashtag "getskinny" attached to a prescription medication journey is worth a raised eyebrow. Mounjaro is a prescription drug indicated for glycemic control in type 2 diabetes and, under the brand name Zepbound, for chronic weight management in adults with obesity or overweight with a weight-related condition. "Getting skinny" is not a medical indication, and framing it that way can set unrealistic expectations about what this medication does and for whom it is appropriate.